Previous close | 730.90 |
Open | 734.60 |
Bid | 761.30 x 0 |
Ask | 761.30 x 0 |
Day's range | 732.00 - 762.50 |
52-week range | 475.45 - 834.50 |
Volume | |
Avg. volume | 2,082,922 |
Market cap | 1.726T |
Beta (5Y monthly) | 0.25 |
PE ratio (TTM) | 35.41 |
EPS (TTM) | 21.50 |
Earnings date | N/A |
Forward dividend & yield | 10.40 (1.37%) |
Ex-dividend date | 25 Mar 2022 |
1y target est | 784.25 |
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate